Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest update is out from SynAct Pharma AB ( (SE:SYNACT) ).
SynAct Pharma AB has announced an increase in the number of shares and votes by 856,625 due to a directed share issue executed in June 2025. This change brings the total number of shares and votes to 49,874,543. The remaining 1,456,500 shares from the issue are scheduled for registration in July 2025, reflecting the company’s ongoing efforts to strengthen its financial position and market presence.
More about SynAct Pharma AB
SynAct Pharma AB is a clinical stage biotechnology company listed on Nasdaq Stockholm, focusing on resolving inflammation through the selective activation of the melanocortin system. The company’s portfolio includes oral and injectable selective melanocortin agonists designed to induce anti-inflammatory activity in autoimmune and inflammatory diseases, aiming to help patients achieve immune balance.
YTD Price Performance: 108.59%
Average Trading Volume: 234,864
Current Market Cap: SEK916.5M
Learn more about SYNACT stock on TipRanks’ Stock Analysis page.